Please try another search
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Ulf Bjorklund | 66 | - | Independent Chairman of the Board |
Olle Hernell | 78 | - | Co-Founder & Director |
Ingemar Kihlstrom | 71 | 2021 | Independent Director |
Asa Hansdotter | 49 | 2021 | Independent Director |
Lennart Lundberg | 70 | 2021 | Member of Scientific Advisory Board |
Kristian Sandberg | 62 | 2020 | Independent Director |
Björn Löwenadler | 71 | - | Member of Scientific Advisory Board |
Carl-Johan Spak | 67 | 2023 | Independent Director |
Rikard Holmdahl | - | - | Member of Scientific Advisory Board |
Solbritt Rantapaa Dahlqvist | - | - | Member of Scientific Advisory Board |
Anders Fasth | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review